Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Calcitonin gene-related peptide antagonism and cluster headache : an emerging new treatment. / Ashina, Håkan; Newman, Lawrence; Ashina, Sait.
I: Neurological Sciences, Bind 38, Nr. 12, 2017, s. 2089-2093.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Calcitonin gene-related peptide antagonism and cluster headache
T2 - an emerging new treatment
AU - Ashina, Håkan
AU - Newman, Lawrence
AU - Ashina, Sait
PY - 2017
Y1 - 2017
N2 - Calcitonin gene-related peptide (CGRP) is a key signaling molecule involved in migraine pathophysiology. Efficacy of CGRP monoclonal antibodies and antagonists in migraine treatment has fueled an increasing interest in the prospect of treating cluster headache (CH) with CGRP antagonism. The exact role of CGRP and its mechanism of action in CH have not been fully clarified. A search for original studies and randomized controlled trials (RCTs) published in English was performed in PubMed and in ClinicalTrials.gov. The search term used was “cluster headache and calcitonin gene related peptide” and “primary headaches and calcitonin gene related peptide.” Reference lists of identified articles were also searched for additional relevant papers. Human experimental studies have reported elevated plasma CGRP levels during both spontaneous and glyceryl trinitrate-induced cluster attacks. CGRP may play an important role in cluster headache pathophysiology. More refined human studies are warranted with regard to assay validation and using larger sample sizes. The results from RCTs may reveal the therapeutic potential of CGRP monoclonal antibodies and antagonists for cluster headache treatment.
AB - Calcitonin gene-related peptide (CGRP) is a key signaling molecule involved in migraine pathophysiology. Efficacy of CGRP monoclonal antibodies and antagonists in migraine treatment has fueled an increasing interest in the prospect of treating cluster headache (CH) with CGRP antagonism. The exact role of CGRP and its mechanism of action in CH have not been fully clarified. A search for original studies and randomized controlled trials (RCTs) published in English was performed in PubMed and in ClinicalTrials.gov. The search term used was “cluster headache and calcitonin gene related peptide” and “primary headaches and calcitonin gene related peptide.” Reference lists of identified articles were also searched for additional relevant papers. Human experimental studies have reported elevated plasma CGRP levels during both spontaneous and glyceryl trinitrate-induced cluster attacks. CGRP may play an important role in cluster headache pathophysiology. More refined human studies are warranted with regard to assay validation and using larger sample sizes. The results from RCTs may reveal the therapeutic potential of CGRP monoclonal antibodies and antagonists for cluster headache treatment.
KW - Antagonism
KW - Calcitonin gene-related peptide
KW - Cluster headache
KW - Pain
KW - Pathophysiology
KW - Trigeminal system
U2 - 10.1007/s10072-017-3101-8
DO - 10.1007/s10072-017-3101-8
M3 - Review
C2 - 28856479
AN - SCOPUS:85028606527
VL - 38
SP - 2089
EP - 2093
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 12
ER -
ID: 261516287